Sildenafil-induced peripheral analgesia and activation of the nitric oxide–cyclic GMP pathway
Authors:
- C.S PatilCPC.S Patil
- Amarjit SinghASAmarjit Singh
- Shrinivas K KulkarniSKShrinivas K Kulkarni
- 1 August 2001
- journal article
- Published by Elsevier in Brain Research
- Vol. 909 (1-2) , 170-178
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Analgesic, Anti-inflammatory and Ulcerogenic activity of a Zinc–Naproxen Complex in Mice and RatsPharmacy and Pharmacology Communications, 1999
- Sildenafil Citrate, a Selective Phosphodiesterase Type 5 Inhibitor:Trends in Endocrinology & Metabolism, 1999
- Molecular Cloning and Expression of Human cGMP-Binding cGMP-Specific Phosphodiesterase (PDE5)Biochemical and Biophysical Research Communications, 1998
- 546C88Drugs of the Future, 1998
- Inducible nitric oxide synthase: what difference does it make?Journal of Clinical Investigation, 1997
- Sildenafil (VIAGRATM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunctionBioorganic & Medicinal Chemistry Letters, 1996
- Sildenafil, a novel effective oral therapy for male erectile dysfunctionBritish Journal of Urology, 1996
- The L-Arginine-Nitric Oxide PathwayNew England Journal of Medicine, 1993
- Peripheral analgesia and activation of the nitric oxide-cyclic GMP pathwayEuropean Journal of Pharmacology, 1990
- Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitorsTrends in Pharmacological Sciences, 1990